Clinical Trials Logo

HIV-1 Infection clinical trials

View clinical trials related to HIV-1 Infection.

Filter by:

NCT ID: NCT03803605 Recruiting - HIV-1 Infection Clinical Trials

Study to Assess Safety and Activity of Combination Therapy of VRC07-523LS and Vorinostat on HIV-infected Persons

Start date: January 2019
Phase: Phase 1
Study type: Interventional

Adult participants (18-64 years old) with HIV-1 Infection on cART with a CD4 T cell count ≥ 350 cells/mm3 and viral suppression for ≥ 24 months will be enrolled on this study. Participants will receive two series of combination therapy consisting of one (1) intravenous (IV) dose of VRC-HIVMAB075-00-AB (VRC07-523LS) followed by 10 oral (PO) doses of Vorinostat (VOR) taken every 72 hours. Each series will last approximately 1 month and the two series will be separated by at least one month. Combination ART is (cART) maintained throughout the study. Participants will be on this study for approximately 36 weeks (or about 9 months). The purpose of this study is to: - Evaluate the safety of two series of a VRC07-523LS infusion followed by multiple oral doses of VOR - Determine if combining VRC07-523LS and VOR can have an impact on non-active HIV virus.

NCT ID: NCT03797014 Not yet recruiting - Hepatitis B Clinical Trials

B/F/TAF Switch Study for HIV-HBV Coinfection

BEST-HBV
Start date: June 2019
Phase: Phase 4
Study type: Interventional

The primary objective of this study is to evaluate the efficacy and safety of fixed dose combination (FDC) bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) in adults coinfected with both HIV-1 and hepatitis B. As this is a switch study, all eligible subjects enrolled will be switched from their current antiretroviral regimen to B/F/TAF will be followed on treatment for 48 weeks.

NCT ID: NCT03774108 Not yet recruiting - PreDiabetes Clinical Trials

Metformin and Systemic Inflammation in HIV

Metfo
Start date: December 15, 2018
Phase: Phase 4
Study type: Interventional

The purposes of this study are to find out if: metformin can be combined with anti-HIV drugs to reduce systemic inflammation measured by the determination of cytokines and other series of serum markers. To determine if the concomitant administration of metformin with TARA improves the immune function on the CD4 T cell count and its relation with the CD8 T cells, during the treatment and after its interruption. To this end, in the present study, patients with prediabetes (who meet the fasting impaired glucose criteria) will be identified and treated with metformin or placebo for 8 weeks, receiving stable TARA and with a CD4 + level> 200 cells / μL. 40 patients from the HIV Unit of the Civil Hospital of Guadalajara "Fray Antonio Alcalde" will be included in this study and the intervention will last 8 weeks.

NCT ID: NCT03772327 Completed - HIV-1-infection Clinical Trials

HIV Adherence Bottle Intervention Trial

HABIT
Start date: May 2015
Phase: N/A
Study type: Interventional

This is a randomized study for participants treated with tenofovir-based antiretroviral drug regimens with a history of suboptimal adherence (detectable HIV RNA twice over the last year). Eligible participants are enrolled, receive routine adherence counseling and are randomized to receive an AdhereTech "smart pill bottle" or not (open label). The "smart pill bottle" quantitates the number of tenofovir-containing pills taken and sends this to a centralized server; if a dose is missed, the participant is contacted by either phone or text. Participants are assessed at baseline and weeks 4, 8, and 12 for tenofovir diphosphate (TFV-DP) levels (by plasma and dried red blood cell spots), HIV RNA level, and adherence using a standardized questionnaire. Primary outcome is change in TFV-DP levels from baseline in the 2 groups.

NCT ID: NCT03757117 Completed - HIV-1-infection Clinical Trials

Gender-Affirmative Transgender Care to Improve the HIV Treatment Cascade

Start date: October 1, 2016
Phase: Phase 4
Study type: Interventional

Public health strategies are urgently needed to improve HIV disparities among transgender women, highly burdened by the epidemic globally, including holistic approaches that address those health needs prioritized by the community. To address this urgent need, a three-phase implementation science study of an integrated HIV service delivery model that combined HIV prevention and treatment services with gender-affirming primary medical care for transgender women was implemented in Lima, Peru, supported by peer navigation to improve outcomes across the HIV continuum of care: regular HIV testing for HIV-uninfected participants and linkage to preventive services; and engagement in treatment resulting in viral suppression for HIV-infected participants.

NCT ID: NCT03743376 Not yet recruiting - HIV-1 Infection Clinical Trials

The HIV Functional Cure Potential of UB-421 in ART Stabilized HIV-1 Patients

Start date: March 2019
Phase: Phase 2
Study type: Interventional

This study evaluate the safety of UB-421 in combination with standard antiretroviral therapy (ART) and the efficacy of HIV reservoir reduction as compared with ART alone in ART stabilized HIV-1 patients

NCT ID: NCT03739866 Recruiting - HIV-1 Infection Clinical Trials

Safety, Pharmacokinetics, and Antiviral Activity of GS-6207 Administered Subcutaneously in HIV-1 Infected Adults

Start date: November 26, 2018
Phase: Phase 1
Study type: Interventional

The primary objective of this study is to evaluate the short-term antiviral activity of GS-6207 compared to placebo in HIV-1 infected adults who are antiretroviral treatment naive or are experienced but capsid inhibitor (CAI) naive.

NCT ID: NCT03729778 Recruiting - HIV Infections Clinical Trials

Impact of HIV-1 and Aging on Mucosal Vaccine Responses

Start date: January 18, 2017
Phase: Phase 4
Study type: Interventional

The purpose of this study is to learn more about both HIV-1 infection and advancing age, alone and in combination, and their association with increased risk of serious infection and impaired response to the Prevnar 13 vaccine.

NCT ID: NCT03729752 Recruiting - HIV-1-infection Clinical Trials

PET Imaging of Radiolabeled Anti-HIV-1 Envelope Monoclonal Antibody (VRC01)

Start date: November 1, 2018
Phase: Phase 1
Study type: Interventional

This is a single center exploratory imaging study involving one intravenous microdose of 89Zr-DFO-VRC01 followed by whole-body PET-MR imaging in HIV infected individuals and healthy volunteers. Imaging data will be obtained from up to four static PE-MR images in order to determine dosimetry and temporal tissue uptake/tissue distribution of 89Zr-DFO-VRC01. This is not a treatment study of the biological activity of 89Zr-DFO-VRC01 to impact HIV persistence.

NCT ID: NCT03719664 Not yet recruiting - HIV-1-infection Clinical Trials

Albuvirtide and 3BNC117 as Long-Acting Maintenance Therapy in Virologically Suppressed Subjects

ABL
Start date: November 2018
Phase: Phase 2
Study type: Interventional

The study is an adaptive, phase 2, multicenter, three-part study to establish the dosage, safety and antiviral activity of combination therapy with albuvirtide (ABT) and 3BNC117 as long-acting maintenance therapy in virologically suppressed subjects with HIV-1 infection.